Homeopathy 2013; 102(04): 274-282
DOI: 10.1016/j.homp.2013.06.001
Original Paper
Copyright © The Faculty of Homeopathy 2013

Anti-proliferative effects of homeopathic medicines on human kidney, colon and breast cancer cells

Shagun Arora
Ayushi Aggarwal
Priyanka Singla
Saras Jyoti
Simran Tandon

Subject Editor:
Further Information

Publication History

Received15 February 2013
revised02 May 2013

accepted21 June 2013

Publication Date:
20 December 2017 (online)

Objective: Homeopathy is controversial, due to the claims made for very high dilutions. Although several theories are proposed to understand the mechanisms of action, none are scientifically verified. This study aimed to investigate the efficacy of the selected homeopathic medicines in specific in vitro cancer models.

Methods: We assessed the cytotoxic activity of selected homeopathic medicines in mother tincture (MT), and ultramolecular dilution (30C, 200C, 1M and 10M) against cell lines deriving from tumors of particular organs, Sarsaparilla (Sars) on ACHN cells (human renal adenocarcinoma), Ruta graveolens (Ruta) on COLO-205 (human colorectal carcinoma), and Phytolacca decandra (Phyto) on MCF-7 (human breast carcinoma). Sars was also tested against Madin–Darby canine kidney (MDCK) cells (a non-malignant cell line). Cytotoxicity was measured using the 3-(4, 5-dimethylthiazolyl-2)-2, 5-diphenyltetrazolium bromide (MTT) method, anti-proliferative activity by trypan blue exclusion assay, apoptosis determined by dual staining the cells with ethidium bromide (EB) and acridine orange (AO) dyes.

Results: MTs and ultra-diluted preparations of the three homeopathic medicines had highly significant effects in the respective cancer cell lines, producing cytotoxicity and a decrease in cell proliferation. The effects were greatest with the MTs, but in all cases and persisted, although to a lesser degree in the ultra-diluted molecular preparations. Sars showed no effect on MDCK cells. In the homeopathic medicine treated cultures, hallmarks of apoptosis were evident including, cell shrinkage, chromatin condensation and DNA fragmentation.

Conclusion: This study provides preliminary laboratory evidence indicating the ability of homeopathic medicines as anticancer agents. Further studies of the action of these homeopathic remedies are warranted.

  • References

  • 1 Milazzo S., Russell N., Ernst E. Efficacy of homeopathic therapy in cancer treatment. Eur J Cancer 2006; 42: 282-289.
  • 2 Homeopathy: an introduction. http://nccam.nih.gov/sites/nccam.nih.gov/files/D439_04-12-2012.pdf .
  • 3 Johannessen H., Bornemann H., Fiorentini G., Costanzos F., Miccinesi G. Prevalence in the use of complementary medicine among cancer patients in Tuscany, Italy. Tumori 2008; 94: 406-410.
  • 4 Angler A., Spix C., Auser F.E., Kameda G., Kaatsch P., Seifert G. Use of homeopathy in pediatric oncology in Germany. Evid Based Complement Alternat Med 2011: 867151.
  • 5 Trager S., Tournigand C., Maindrault F. et al. Use of complementary medicine by cancer patients in a French oncology department. Bull Cancer 2007; 94: 1017-1025.
  • 6 Banerji P., Campbell D.R. Cancer patients treated with the Banerji protocols utilizing homoeopathic medicine: a best case series program of the National Cancer Institute USA. Oncol Rep 2008; 20: 69-74.
  • 7 Pathak S., Multani A.S., Banerji P. Ruta 6 selectively induces cell death in brain cancer cells but proliferation in normal peripheral blood lymphocytes: a novel treatment for human brain cancer. Int J Oncol 2003; 23: 975-982.
  • 8 Frenkel M., Mishra B., Yang P., Cohen L., Sen S., Banerji P., Banerji P. Cytotoxic effects of ultra diluted remedies on breast cancer cells. Int J Oncol 2010; 36: 395-403.
  • 9 Eldridge L. Green light for homeopathic medicine in cancer treatment. 2009. http://lungcancer.about.com/b/2009/04/16/green-light-for-homeopathic-medicine-in-cancer-treatment.html.
  • 10 Biswas S., Pathak Bhattacharjee N., Das J., Khuda-Bukhsh A. Efficacy of the potentized homeopathic drug, Carcinosin 200, fed alone and in combination with another drug, Chelidonium 200, in amelioration of p-dimethylaminoazobenzene-induced hepatocarcinogenesis in mice. J Alternat Complement Med 2005; 11: 839-854.
  • 11 Siegel R., DeSantis C., Virgo K. et al. Cancer treatment and survivorship statistics. CA Cancer J Clin 2012; 2012 (62) 220-241.
  • 12 Pischon T., Lahmann P., Boeing H. et al. Body size and risk of renal cell carcinoma in the European Prospective Investigation into Cancer and Nutrition (EPIC). Int J Cancer 2006; 118: 728-738.
  • 13 Vigneri P., Frasca F., Sciacca L. et al. Diabetes and cancer. Endocrine-Relat Cancer 2009; 16: 1103-1123.
  • 14 Hartmann A., Jenssen T., Holdaas H. Diabetes, chronic kidney disease and cancer risk. Nephrol Dial Transplant 2012: 1-3.
  • 15 Van Meerloo J., Kaspers G.J., Cloos J. Cell sensitivity assays: the MTT assay. Methods Mol Biol 2011; 731: 237-245.
  • 16 Eckstein N., Servan K., Girard L. et al. Epidermal growth factor receptor pathway analysis identifies amphiregulin as a key factor for cisplatin resistance of human breast cancer cells. J Biol Chem 2008; 283: 739-750.
  • 17 Oberschmidt O., Hanauske A., Rehmann F., Strohfeldt K., Sweeney N., Tacke M. Activity of [1,2-di(cyclopentadienyl)-1,2-di(p-N,Ndimethylaminophenyl)-ethanediyl] titanium dichloride against tumor colony-forming units. Anti-Cancer Drugs 2005; 16: 1071-1073.
  • 18 Westmose C., Gyrd-Hansen M., Lykkesfeldt A., Issinger O., Stenvang J. Breast cancer cells with acquired antiestrogen resistance are sensitized to cisplatin-induced cell death. Mol Cancer Ther 2007; 6: 1869-1876.
  • 19 Hisham S., Ariffin Z., Haryani W., Omar W. Intrinsic anticarcinogenic effects of Piper sarmentosum ethanolic extract on a human hepatoma cell line. Cancer Cell Int 2009; 10: 1475-1480.
  • 20 Guimarães F., Abud A., Oliveira S. et al. Stimulation of lymphocyte anti-melanoma activity by co-cultured macrophages activated by complex homeopathic medication. BMC Cancer 2009; 9: 293-304.
  • 21 Witt C., Bluth M., Albrecht H. In vitro evidences for an effect of high homeopathic potencies – a systematic review of the literature. Complement Ther Med 2007; 15: 128-138.
  • 22 Olsen B.R. Life without perlecan has its problems. J Cell Biochem 1999; 147: 909-912.
  • 23 Guimarães F., Andrade L., Martins S. et al. In vitro and in vivo anticancer properties of a Calcarea carbonica derivative complex (M8) treatment in a murine melanoma model. BMC Cancer 2010; 10: 113.
  • 24 Sunila E.S., Kuttan R., Preethi K.C., Kuttan G. Dynamized preparations in cell culture. Evid Based Complement Alternat Med 2009; 6 (02) 257-263.
  • 25 Biswas R., Mandal S., Dutta S., Bhattacharyya S., Boujedaini N., Khuda-Bukhsh A. Thujone-rich fraction of Thuja occidentalis demonstrates major anti-cancer potentials: evidences from in vitro studies on A375 cells. Evid Based Complement Alternat Med 2011 Article ID 568148.
  • 26 Kroemer G., Galluzzi L., Vandenabeele P. et al. Classification of cell death: recommendations of the Nomenclature Committee on Cell Death. Cell Death Differ 2009; 16: 3-11.
  • 27 Baskić D., Popović S., Ristić P., Arsenijević N.N. Analysis of cycloheximide-induced apoptosis in human leukocytes: fluorescence microscopy using annexin V/propidium iodide versus acridine orange/ethidium bromide. Cell Biol Int 2006; 11: 924-932.
  • 28 Bustillo S., Lucero H., Leiva L.C., Acosta O., Kier Joffé E.B., Gorodner J.O. Cytotoxicity and morphological analysis of cell death induced by Bothrops venoms from the northeast of Argentina. J Venom Anim Toxins 2009; 15: 28-42.